International Medical Journal, Vol. 25., Iss. 4, 2019, P. 90−96.
EXPERIENCE OF AFLIBERCEPT APPLICATION IN PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION
Kharkiv Medical Academy of Postgraduate Education
Kharkiv National Medical University
Medical Center for Outpatient Ophthalmic Surgery "OKO", Kharkiv, Ukraine
Age−related macular degeneration is a threatening pathology, gradually leading to a complete loss of central vision, which adversely affects an individual physically and emotionally as well as socially, reducing the life quality of such patients. To analyze the anatomical and functional results of intravitreal injections of aflibercept in the patients with exudative age−related macular degeneration, 47 patients a were prospectively studied. Intravitreal injections of aflibercept were performed by the same surgeon under aseptic operating conditions at a dosage of 2 mg, which was 0.05 ml of the drug. All patients underwent a comprehensive ophthalmic examination, which included visometry, autoceratorefractometry, tonometry, biomicroscopy, and ophthalmoscopy under medical mydriasis, as well as optical coherence tomography. The study took place before the intravitreal administration of aflibercept, one month after each of the three loading injections, 4, 8, and 12 weeks, respectively, after the start of treatment, and 4 weeks after the fourth injection, which was performed 8 weeks after the third loading. The total follow−up period was 24 weeks. For assessing the anatomical and functional efficiency of the treatment the changes in visual acuity, which were adjusted as well as those in the central retinal thickness according to optical coherence tomography were accepted as the criteria. The treatment results showed a significant increase in visual acuity of patients with the most significant increase in the index at week 12 from the beginning of therapy, as well as to a statistically significant decrease in the central retinal thickness within six months of observation. It is obvious that a consistent use of this drug is necessary to achieve stable treatment results.
Key words: exudative age−related macular degeneration, visual acuity, central retinal thickness, intravitreal antiangiogenic therapy.
1. Global prevalence of age−related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta−analysis / Wan Ling Wong, Xinyi Su, Xiang Li [et al.].− URL: www.thelancet. com/lancetgh Vol 2 February 2014
2. Bikbov M. M. Vozrastnaya makulyarnaya degeneraciya / M. M. Bikbov, R. R. Fajzrahmanov, A. L. Yarmuhametova.− M.: Aprel, 2013.− 196 s.
3. Treatment of Exudative Age−related Macular Degeneration: Focus on Aflibercept / A. Garcia−Layana, M. S. Figueroa, J. Araiz [et al.] // Drugs Aging.− 2015.− Vol. 32 (10).− P. 797−807.− doi: 10.1007/ s40266−015−0300−y.Review
4. Risk Factors and Biomarkers of Age−Related Macular Degeneration / G. Lambert Nathan, K. Malkit Singh, E. l. Hanan [et al.] // ProgRetin Eye Res.− 2016.− Vol. 54.− P. 64−102.− doi: 10.1016/j.preteyeres.2016.04.003
5. Arnold J. J. Age−related macular degeneration: antivascular endothelial growth factor treatment / J. J. Arnold // BMJ Clin. Evid.− 2016.− 0701.
6. Farnoodian M. Negative Regulators of Angiogenesis, Ocular Vascular Homeostasis, and Pathogenesis and Treatment of Exudative AMD / M. Farnoodian, C. M. Sorenson, N. Sheibani // J. Ophthalmic Vis. Res.− 2018.− Vol. 13 (4).− P. 470−486.− doi: 10.4103/ jovr.jovr_67_18
7. Cost and Selection of Ophthalmic Anti−Vascular Endothelial Growth Factor Agents / E. Li, P. B. Greenberg, I. Voruganti, M. G. Krzystolik // R I Med. J.− 2016.− Vol. 99 (5).− P. 15−17.
8. A single−arm, investigator−initiated study of the efficacy, safety and tolerability of intravitrealaflibercept injection in subjects with exudative age−related macular degeneration, previously treated with ranibizumab or bevacizumab: 6−month interim analysis / R. P. Singh, S. Srivastava, J. P. Ehlers [et al.] // Br. J. Ophthalmol.− 2014.− Vol. 98, Suppl. 1.− P. 22−27.− doi: 10.1136/ bjophthalmol−2013−304798
9. Intravitreal combination of dexamethasone sodium phosphate and bevacizumab in the treatment of exudative AMD / N. Vakalis, G. Echiadis, A. Pervena [et al.] // Sci. Rep.− 2015.− Vol. 27 (5).− P. 8627.− doi: 10.1038/srep08627
10. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age−related macular degeneration: a randomised, prospective trial / C. Zehetner, M. T. Kralinger, Y. S. Modi [et al.] // Acta Ophthalmol.− 2015.− Vol. 93 (2).− P. 154−159.− doi: 10.1111/aos.12604
11. TREX−AMD Study Group.Prospective Trial of Treatand−Extend versus Monthly Dosing for Neovascular Age−Related Macular Degeneration: TREX−AMD 1−Year Results / C. C. Wykoff, D. E. Croft, D. M. Brown [et al.] // Ophthalmology.− 2015.− Vol. 122 (12).− P. 2514−2522.− doi: 10.1016/j.ophtha.2015.08.009
12. Chia K. J. W. The Impact of Switching Anti−Vascular Endothelial Growth Factor Therapy in the Management of Exudative Age−Related Macular Degeneration / K. J. W. Chia, D. V. Gunasekeran, A. Laude // Ophthalmic. Surg. Lasers Imaging Retina.− 2017.− Vol. 48 (10).− P. 859−869.− doi: 10.3928/23258160−20170928−14
13. Outcomes of patients with exudative age−related macular degeneration treated with antivascular endothelial growth factor therapy for three or more years: A Review of Current Outcomes / V. L. Qin, J. Young, F. Q. Silva [et al.] // Retina.− 2018.− Vol. 38 (8).− P. 1500−1508.− doi: 10.1097/IAE.0000000000001753
14. Individualized management of patients with exudative AMD, IOI protocol: Injection−observationalindividualization / O. Semoun, S. Y. Cohen, M. Srour [et al.] // J. Fr. Ophtalmol.− 2017.− Vol. 40 (3).− P. 169−176.− doi: 10.1016/j.jfo.2016.12.003
15. Switching to aflibercept among patients with treatmentresistant neovascular age−related macular degeneration: a systematic review with meta−analysis / K. Spooner, T. Hong, W. Wijeyakumar, A. A. Chang // Clin. Ophthalmol.− 2017.− Vol. 6 (11).− P. 161−177.− doi: 10.2147/OPTH.S125676
16. Papadopoulos Z. Aflibercept: A review of its effect on the treatment of exudative age−related macular degeneration / Z. Papadopoulos // Eur. J. Ophthalmol.− 2019.− Vol. 29 (4).− P. 368−378.− doi: 0.1177/1120672119832432
17. One−year outcomes of fixed treatment of intravitrealaflibercept for exudative age−related macular degeneration and the factor of visual prognosis / A. Ono, C. Shiragami, S. Manabe [et al.] // Medicine (Baltimore).− 2018.− Vol. 97 (31).− e11737.− doi: 10.1097/MD.0000000000011737
18. Aflibercept after ranibizumabintravitreal injection in exudative age−related macular degeneration: The ARI2 Study / R. Blanco−Garavito, C. Jung, J. Uzzan [et al.] // Retina.− 2018.− Vol. 38 (12).− P. 2285−2292.− doi: 10.1097/IAE.0000000000001928
19. Clinicaland electrophysiological evaluation after intravitrealziv−aflibercept for exudastive age−related macular degeneration / J. R. de Oliveira Dias, G. C. de Andrade, V. F. Kniggendorf [et al.] // Retina.− 2017.− Vol. 37 (8).− P. 1499−1507.− doi: 10.1097/ IAE.0000000000001385
20. A single−arm, investigator−initiated study of the efficacy, safety, and tolerability of intravitrealaflibercept injection in subjects with exudative age−related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12−month analysis / R. P. Singh, S. K. Srivastava, J. P. Ehlers [et al.] // Clin. Ophthalmol.− 2015.− Vol. 22 (90).− P. 1759−1766.− doi: 10.2147/OPTH.S87043
21. Response to Aflibercept Therapy in Three Types of Choroidal Neovascular Membrane in Neovascular AgeRelated Macular Degeneration: Real−Life Evidence in the Czech Republic / J. Nemcansky, A. Stepanov, M. Koubek [et al.] // J. Ophthalmol.− 2019.− Vol. 10.− 2635689.− doi: 10.1155/2019/2635689